|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Diabetes mellitus and electrolyte disorders显示文摘Diabetic patients frequently develop a constellation of electrolyte disorders. These disturbances are particularly common in decompensated diabetics, especially in the context of diabetic ketoacidosis or nonketotic hyperglycemic hyperosmolar syndrome. These patients are markedly potassium-, magnesium- and phosphatedepleted. Diabetes mellitus(DM) is linked to both hypo- and hyper-natremia reflecting the coexistence of hyperglycemia-related mechanisms, which tend to change serum sodium to opposite directions. The most important causal factor of chronic hyperkalemia in diabetic individuals is the syndrome of hyporeninemic hypoaldosteronism. Impaired renal function, potassiumsparing drugs, hypertonicity and insulin deficiency are also involved in the development of hyperkalemia. This article provides an overview of the electrolyte disturbances occurring in DM and describes the underlying mechanisms. This insight should pave the way for pathophysiology-directed therapy, thus contributing to the avoidance of the several deleterious effects associated with electrolyte disorders and their treatment. | George Liamis Evangelos Liberopoulos Fotios Barkas Moses Elisaf | 2014 | World Journal of Clinical Cases2014，2，10： | 13 |
| 2 | Attainment of multifactorial treatment targets among the elderly in a lipid clinic显示文摘ObjectiveTo 检验目标成就类脂化合物阴沉, antihypertensive 和 antidiabetic 治疗在在在 Greece.MethodsThis 的一所大学医院的一个专家背景老是包括连续题目 ≥ 的回顾的研究;65 岁(n = 465 ) 与后续 ≥3 年。低密度的脂蛋白胆固醇( LDL-C ),血压( BP )和 glycated 血红素( HbA1c )目标成就根据心病学/欧洲人动脉粥样硬化社会( ESC/EAS )的欧洲社会被记录,为糖尿病( EASD ) guidelines.ResultsThe LDL-C 目标的学习的高血压( ESH ) /ESC 和欧洲协会的欧洲社会被27%很高、高、中等的风险病人,48%和62%分别地达到。更高完成的那些收到的 statin + ezetimibe 与那些收到的 statin monotherapy 相比 LDL-C 目标成就评价(48% 对 33% , P <0.05 ) 。糖尿病的题目, 71% 有 BP <140/85 mmHg,当没有糖尿病, 78% 那些有 BP < 时;140/90 mmHg。非糖尿病的个人(86%) 的一个更高的比例有 BP <150/90 mmHg。另外,有糖尿病的那些的一个更高的比例有 HbA1c <8% 而非 <7%(88% 和 47% ,分别地) 。笔记,从三个非糖尿病的个人的几乎一个和从十个糖尿病的个人的一个在一所大学医院,在非最优的 LDL-C 的老遗体的一个高比例, BP 和 HbA1c 层次的一个专家背景完成了所有三治疗 targets.ConclusionsEven。药联合的使用能改进 multifactorial 治疗目标成就,当不太严格的目标能更容易在这张人口被完成时。 | Fotios Barkas Evangelos Liberopoulos Eleftherios Klouras Angelos Liontos Moses Elisaf | 2015 | Journal of Geriatric Cardiology2015，12，3： | 5 |
| 3 | Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia显示文摘AIM:To assess the effect of different hypolipidemic treatment strategies on glycemic profile in mixed dyslipidemia patients.METHODS:This is a prespecified analysis of a prospective,randomized,open-label,blinded end point(PROBE)study(ClinicalTrials.gov identifier:NCT01010516).Patients(n=100)with mixed dyslipidemia on a standard statin dose who had not achieved lipid targets were randomized to switch to the highest dose of rosuvastatin(40 mg/d)or to add-on-statin extended release nicotinic acid(ER-NA)/laropiprant(LRPT)or to addon-statin micronised fenofibrate for a total of 3 mo.Fasting plasma glucose(FPG),glycosylated hemoglobin(HbA1c),homeostasis model assessment of insulin resistance(HOMA-IR)index and lipid profile were evaluated at baseline and 3 mo after treatment intervention.RESULTS:FPG increased in add-on ER-NA/LRPT and rosuvastatin monotherapy groups by 9.7%and 4.4%,respectively(P<0.01 between the 2 groups and compared with baseline),while it did not significantly change in the add-on fenofibrate group.Similarly,HbA1c increased by 0.3%in add-on ER-NA/LRPT group and by 0.2%in the rosuvastatin monotherapy group(P<0.01 for all comparisons vs baseline and for the comparison between the 2 groups),while no significant change was reported in the add-on fenofibrate group.HOMA-IR increased by 65%in add-on ER-NA/LRPT and by 14%in rosuvastatin monotherapy group,while it decreased by 6%in the add-on fenofibrate group(P<0.01 vs baseline and for all comparisons among the groups).Non-HDL-C decreased in all groups(by 237%,247%and 7%in the rosuvastatin,ER-NA/LRPT and fenofibrate group,respectively,P<0.01 for all vs baseline and P<0.01 for all vs with fenofibrate group).CONCLUSION:Both addition of ER-NA/LRPT and switch to the highest dose of rosuvastatin deteriorated glycemic profile in patients with mixed dyslipidemia,while add-on fenofibrate seems to increase insulin sensitivity. | Anastazia Kei Evangelos Liberopoulos Moses Elisaf | 2013 | World Journal of Diabetes2013，4，6： | 3 |
| 4 | Statin escape phenomenon: Fact or fiction?显示文摘AIM To evaluate the presence of the so called 'statin escape' phenomenon among hyperlipidemic subjects attending a lipid clinic. METHODS This was a retrospective analysis of 1240 hyperlipidemic individuals followed-up for ≥ 3 years. We excluded those individuals meeting one of the following criteria: Use of statin therapy at baseline visit, discontinuation of statin treatment at most recent visit, change in statin treatment during follow-up and poor compliance to treatment. Statin escape phenomenon was defined as an increase in lowdensity lipoprotein cholesterol(LDL-C) levels at the most recent visit by > 10% compared with the value at 6 mo following initiation of statin treatment. RESULTS Of 181 eligible subjects, 31% exhibited the statin escape phenomenon. No major differences regarding baseline characteristics were found between statin escapers and non-statin escapers. Both escapes and non-escapes had similar baseline LDL-C levels [174(152-189) and 177(152-205) mg/d L, respectively]. In comparison with nonescapers, statin escapers demonstrated lower LDL-C levels at 6 mo after treatment initiation [88(78-97) mg/d L vs 109(91-129) mg/d L, P < 0.05], but higher levels at the most recent visit [103(96-118) mg/d L vs 94(79-114) mg/d L, P < 0.05]. CONCLUSION These data confirm the existence of an escape phenomenon among statin-treated individuals. The clinical significance of this phenomenon remains uncertain. | Fotios Barkas Moses Elisaf Eleftherios Klouras Theodora Dimitriou Nikolaos Tentolouris Evangelos Liberopoulos | 2017 | World Journal of Experimental Medicine2017，7，1： | 2 |
| 5 | Dyslipidemia in patients with thyroid disorders 显示文摘 | Liberopoulos EN Elisaf MS | 2002 | Hormones (Athens)2002，1，4： | 1 |
| 6 | Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study显示文摘 | T. D. Filippatos D. N. Kiortsis E. N. Liberopoulos M. Georgoula D. P. Mikhailidis M. S. Elisaf | 2005 | Current Medical Research and Opinion?2005，，12： | 1 |
| 7 | Statin pleiotropyagainst renal injury显示文摘 | Kostapanos MS Liberopoulos EN Elisaf MS | 2009 | J Cardiometab Syndr2009，4，1： | 1 |
| 8 | Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals 显示文摘 | MILIONIS HJ LIBEROPOULOS E GOUDEVENOSJ | 2005 | Int J Cardiol2005，99，2： | 1 |
| 9 | The effect of apolipoprotein E polymorphism on the response to lipid - lowering treatment with atorvastatin or fenofibrate 显示文摘 | Christidis DS Liberopoulos EN Kakafika AI | 2006 | J Cardiovasc Pharma- col Ther2006，11，： | 1 |
| 10 | Production control of manufacturing systems with production rate-dependent failure rates 显示文摘 | LIBEROPOULOS G CARAMANIS M | 1994 | IEEE Transactions Automatic Control1994，39，： | 1 |
| 11 | Effects of thyroid dysfunction on lipid profile显示文摘 | Rizos CV Elisaf MS Liberopoulos EN | 2011 | Open Cardiovasc Med J2011，5，： | 1 |
| 12 | Apolipoprotein E and renal disease显示文摘 | Liberopoulos E Siamopoulos K Elisaf M | 2004 | Am J Kidney Dis2004，43，2： | 1 |
| 13 | Diverging trends in cardiovascular morbidity and mortality in a low risk popu- lation显示文摘 | Chimonas T Fanouraki I Liberopoulos E N | 2009 | EurJ Epidemiol2009，24，8： | 1 |
| 14 | Dyslipidemia in patients with thyroid disorders显示文摘 | Liberopoulos EN Elisaf MS | 2002 | Hormones2002，1，4： | 1 |
| 15 | Pleiotropic effects of thiazolidinediones 显示文摘 | Rizos CV Liberopoulos EN Mikhailidis DP | 2008 | Expert Opin Pharmacother2008，9，7： | 1 |
| 16 | Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome:a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluatio显示文摘 | Athyros VG Mikhailidis DP Liberopoulos EN | | 0，，01： | 1 |
| 17 | Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?显示文摘 | Sofia G. Tsouli Evangelos N. Liberopoulos Dimitri P. Mikhailidis Vasilios G. Athyros Moses S. Elisaf | 2006 | Metabolism2006，，10： | 1 |
| 18 | Pleiotropic effects of nicotinic acid:beyond high density lipoprotein cholesterol elevation显示文摘 | Florentin M Liberopoulos EN Kei A | | 0，，： | 1 |
| 19 | Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study显示文摘 | T. D. Filippatos D. N. Kiortsis E. N. Liberopoulos M. Georgoula D. P. Mikhailidis M. S. Elisaf | 2005 | Current Medical Research and Opinion?2005，，12： | 1 |
| 20 | The role of C-reactive protein in atherosclerotie cardiovascular disease: an overview 显示文摘 | Nakou E S Liberopoulos E N Milionis H J | 2008 | Curt Vasc Pharmacol2008，6，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员